Masafumi Fukagawa, MD, PhD

Vice Dean, Tokai University School of Medicine, Isehara Japan

Professor and Chairman, Department of Internal Medicine

Chief, Division of Nephrology, Endocrinology and Metabolism

Masafumi Fukagawa, MD, PhD received his MD in 1983 from University of Tokyo School of Medicine, Tokyo, Japan. Following subspecialty training and PhD program in Tokyo, he was Research Fellow at Vanderbilt University School of Medicine, Nashville, TN (USA) until 1995. 

From 2000 to 2009, Dr Fukagawa was Associate Professor and Director of the Division of Nephrology and Kidney Center at Kobe University School of Medicine, Kobe, Japan, where he established a new nephrology program and trained numbers of medical students, residents and fellows from Japan and other Asian countries. Since 2009, he has moved to Tokai University School of Medicine, Isehara, Japan, as Professor of Medicine and the Director of Division of Nephrology, Endocrinology, and Metabolism. From 2020, he is Chairman of Department of Internal Medicine. From 2021, he also serves as Vice Dean. 

Dr. Fukagawa’s major research fields are electrolyte disorders including mineral metabolism and uremic toxins, in which fields he has published more than 500 clinical and basic papers and reviews. 

He was a member of KDIGO Work Group on CKD-MBD global guidelines and also served as a member for guideline update. He also chaired the committee for the new version of Japanese clinical guideline on CKD-MBD. From 2020, he is a member of Executive Committee of KDIGO.

For International Society of Nephrology, he is a member of Educational Committee and North and East Asia Regional Board for ISN.

He was International Associate Editor of the Clinical Journal of the American Society of Nephrology (CJASN) (2005-2010) and currently serves as Associate Editor for Journal of Bone and Mineral Metabolism and Clin Exp Nephrol. He is Editorial Board member for Kidney International, Clinical Journal of the American Society of Nephrology, Nephrology Dialysis Transplantation, Therapeutic Apheresis Dialysis, JBMR Plus, and Kidney Medicine.

Click here to see relevant disclosures.